Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5640_Библиотеки_им_академика_М_И_Перельмана.pdf
Unlocking the Potential of Gene Therapy: Principles and Therapeutic Applications 469
Blending of viral and cellular membranes begins the intern ali-
zation of the viral nucleus [
20]; the viral envelope unites with the
cell membrane. Envelope glycoprotein (Env) of retroviruses is
accountable for deciding tropism. Fastening of Env to cellular
receptor and combination of viral and cellular membranes are the
initial stages of entry of virus.
Retroviruses pursue an unusual replication cycle during transformation of single-stranded RNAs into double-stranded DNA in
the infected cell. Viral DNA production occurs in cytoplasm by
virus-encoded DNA polymerase, which is known as reverse transcriptase. Viral DNA comes inside the nucleus, and viral DNA takes
the loop or ring form. Ring-formed DNA works as a draft for RNA
synthesis [
21]. While viral DNA comes into the nucleus, it incor-
porates with the DNA of the host cell. Retroviruses transfer their
DNA to the host cell genome at some stage in mitotic division. The
majority of retroviruses infect host cells that are actively dividing in
mitotic division. This feature guards normal tissue and targets the
cancerous cells. Infected cells are then transcribed and spliced. Viral
RNA is transported to cytoplasm and then translated. Spliced viral
RNA is packed into viral particles. Retroviral particles encase two
copies of complete viral RNA, having entire genetic information
essential for virus replication, with capsid [
19]. Studies found that
definite packaging of retroviral genomic RNA was carried out.
Retroviral genome packaging is usually found flanked by the binding donor (SD) region and the gag start codon. Virion maturation
happens through the budding of the particle from the cell [
7]. The
translational method of the host produces and transforms viral
proteins. Recently produced viral proteins and complete RNAs
unite to produce a new virus form. A retrovirus infects the target
cell through offering communication amid viral envelope protein
and cell exterior receptor on the target cell. The virus then presented to the site where its single-stranded RNA alters into doublestranded DNA. Double-stranded DNA is presented to the nucleus
and incorporated into the host cell genome. Firm binding of viral
DNA to the host genome is beneficial because it will offer longterm expression of transgenes necessary for remedial effect. One of
the limitations of present retroviral transfer techniques is that they
are not precise to types of target cells [
20]. The capability of retro-
viruses to penetrate its genomes to host cell allows them to make
stable alterations in the host cell. This stability is better than other
viruses such as adenovirus, herpes simplex virus, and papilloma
virus.
3.4 Lentivirus (LV)
Lentivirus (LV) is composed of a single-stranded RNA and has
been extensively used to deliver gene. As a gene delivery means,
LV incorporation of the host genome may lead to needless
non-target insertion mutations, which is a safety threat. LV is less
commonly used than AAV and AdV. Integration-deficient lentiviral
470 Vijay Kumar
vectors (IDLV) have high transduction competence of LVs and
show reduced insertion mutations.
Lentiviral systems provide gene delivery to non-dividing cells.
This attribute is a benefit for a variety of gene therapy purposes
utilized in aiming in post-mitotic and extremely differentiated cells.
Because of this, lentiviral vectors can be utilized for transgene
expression to neuron cells [
mic structure; they have additional genes which control viral gene
expression, adjust viral replication in infected cells, and are also
associated with the maintenance of infection [
lentiviral vectors is based on the type of envelope protein utilized
for virus production [7]. The mainly utilized Env protein is “vesicular stomatitis virus glycoprotein (VSV-G).” This protein allows
the virus maximum titration values and a high tropism [
viral vectors do not involve breaking of the nuclear membrane for
incorporation. Often, pseudotype lentiviral vectors are developed
by vesicular stomatitis virus envelope (VSV-G). VSV-G provides
large host-cell variety and increased vector particle stability, which
are suitable for ex vivo gene alteration. The latest-designed lentiviral gene transfer systems have several features of retroviral systems. A viral genome incorporates with host chromosomes, and
genes that are required to stay forever are placed [
20]. Lentiviruses have a complex geno-
22]. Tropism of
23]. Lenti-
20].
4 Conclusion
In conclusion, gene therapy has emerged as a transformative
approach with the potential to correct and replace faulty genes,
thus treating various genetic and acquired diseases, including cancer, immunodeficiencies, and cardiovascular disorders. Advances in
genetic engineering and molecular biology have enabled the development of sophisticated viral and non-viral vectors for gene delivery, each with unique properties suited to specific applications. Viral
vectors, including adenovirus, adeno-associated virus, retrovirus,
and lentivirus, have shown significant promise for in vivo and
ex vivo gene transfer. However, these systems must address challenges like immune responses, insertional mutagenesis, and cellspecific targeting to improve their efficacy and safety.
ontinuous r
The c
the future success of gene therapy. Stable integration, targeted
delivery, and long-term gene expression are critical features for
effective therapeutic outcomes. Hybrid systems combining both
viral and non-viral components offer a potential pathway for
enhancing delivery precision while minimizing adverse effects.
As gene
ing currently untreatable genetic disorders and acquired diseases at
a molecular level. Regulatory and ethical considerations will also
play a role in defining the path forward for gene therapy as a widely
therapy technology advances, it brings hope for treat-
efinement of gene delivery systems is key to
References
Unlocking the Potential of Gene Therapy: Principles and Therapeutic Applications 471
accepted medical treatment. With further research, gene therapy is
positioned to become an integral component of modern medicine,
providing new therapeutic avenues and transforming clinical
practice.
1. Jones CH, Chen CK, Ravikrishnan A, Rane S,
Pfeifer BA (2013) Overcoming nonviral gene
delivery barriers: perspective and future. Mol
Pharm 10:4082–4098
2. Friedmann T, Roblin R (1972) Gene therapy
for human genetic disease. Science 175:949–
955
3. Han S-O, Mahato RI, Sung YK, Kim SW
(2000) Development of biomaterials for gene
therapy. Mol Ther 2:302–317
4. Mahato RI, Smith LC, Rolland A (1999) Pharmaceutical perspectives of nonviral gene therapy. Adv Genet 41:95–156
5. Nayerossadat N, Maedeh T, Ali PA (2012)
Viral and nonviral delivery systems for gene
delivery. Adv Biomed Res 1:27–31
6. Mali S (2013) Delivery systems for gene therapy. Indian J Hum Genet 19:3–8
7. Escors D, Brecpot K (2010) Lentiviral vectors
in gene therapy: their current status and future
potential. Arch Immunol Ther Exp 58:107–
119
8. Medina-Kauwe LK (2003) Endocytosis of adenovirus and adenovirus capsid proteins. Adv
Drug Deliv Rev 55:1485–1496
9. Majhen D, Ambriovic-Ristov A (2006) Adenoviral vectors-how to use them in cancer gene
therapy? Virus Res 119:121–133
10. Rowe WP, Huebner RJ, Gilmore LK, Parrott
RH, Ward TG (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue
culture. Proc Soc Exp Biol Med 84(3):
570–573
11. Ginsberg HS, Prince GA (1994) The molecular
basis of adenovirus pathogenesis. Infect Agents
Dis 3:1–8
12. Dinh AT, Theofanous T, Mitragotri S (2005) A
model for intracellular trafficking of adenoviral
vectors. Biophys J 89:1574–1588
13. Khare R, Chen CY, Weaver EA, Barry MA
(2011) Advances and future challenges in adenoviral vector pharmacology and targeting.
Curr Gene Ther 11:241–258
14. Muzzonigro TS, Ghivizzani SC, Robbins PD,
Evans CH (1999) The role of gene therapy:
fact or fiction? Clin Sports Med 18:223–237
15. Reynolds PN, Feng M, Curiel DT (1999) Chi-
meric viral vectors – the best of both worlds?
Mol Med Today 4:25–31
16. Navarro J, Risco TM, Schattman G (2008)
Gene therapy and Intracytoplasmatic sperm
injection (ICSI) – a review. Placenta 29:S193–
S199
17. Hermonat PL, Muzyczka N (1984) Use of
adeno-associated virus as a mammalian DNA
cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc
Natl Acad Sci USA 81:6466–6470
18. El-Aneed A (2004) An overview of current
delivery systems in cancer gene therapy. J Control Release 94:1–14
19. Hu WS, Pathak VK (2000) Design of retroviral
vectors and helper cells for gene therapy. Pharmacol Rev 52:494–507
20. Yi Y, Noh MJ, Lee KH (2011) Current
advances in retroviral gene therapy. Curr Gene
Ther 11:218–228
21. Olsen JC, Swanstorm R (1985) A new pathway
in the generation of defective retrovirus DNA.
Virol J 56:779–789
22. Howarth JL, Lee YB, Uney JB (2010) Using
viral vectors as gene transfer tools. Cell Biol
Toxicol 26:1–20
23. Osten P
vectors: a wide range of choices and high level
services. Handb Exp Pharmacol 178:177–202
, Grinevich V, Cetin A (2007) Viral
Chapter 21
Cell-Based Therapies and Drug Delivery: Advancements
and Challenges
Pradeep Kumar Ram, Amit Kumar Jha, Kritika Dhial,
and Abhishek Pathak
Abstract
Cell therapy represents an innovative approach in regenerative medicine, utilizing living cells to treat various
diseases and disorders. This therapy may involve cell replacement, as in red blood cell infusion for anemia,
platelet administration, or immune system regulation through T lymphocytes. Stem cells and progenitor
cells, which can create new cells, are also essential for regenerative therapies. Technologies in cell therapy,
including viral vector gene modification and genome editing (such as CRISPR-Cas9), have enabled
targeted treatments for blood cancers, genetic disorders, and more. Immune cell-based therapies, particularly CAR T-cell treatments, have shown promising results for cancers. Veterinary applications of cell
therapy, such as ligament repair in horses, highlight the expanding potential across species. Cell therapy is
still in its developmental stages, but its remarkable potential for treating cardiovascular, neurological, and
immune-related disorders continues to grow. Collaboration between clinical researchers and laboratory
scientists remains essential to enhance therapy efficacy and address technological challenges. This evolving
field aligns with biotechnological advancements and signifies a transformative future in medicine and animal
healthcare.
Key words Cell therapy, Regenerative medicine, Stem cells, Immune cell therapy, Gene modification,
CAR T-cell, Viral vector, Biotechnology
1 Introduction
A specific medical condition can be treated by the use of cell
therapy, which involves the introduction of living cells into the
body of a patient. It may involve the replacement of lost cells,
such as the infusion of red blood cells to treat anemia, the administration of platelets for cases of low platelet count that require
immediate attention, or the application of T lymphocytes to regulate the immune system and treat cancer, for example. The term
“cell replacement therapy” refers to this particular type of cellular
therapy, which is utilized rather frequently in medical programs that
encompass both human and animal applications. The therapy of
473
474 Pradeep Kumar Ram et al.
Fig. 1 Cell therapy for dif ferent organs of the body
cells can also be exploited for the goal of regenerative medicine
1). Stem cells and progenitor cells, which are cells that have
(Fig.
the ability to make new cells, are utilized in the event that these
conditions present themselves (Fig. 2
cutting-edge
breakthrough
the transformative power of biotechnology. Cell therapies, just like
other treatments, rely heavily on the remarkable scientific breakthroughs and technological advancements that have taken place.
There are several cell-based therapies currently in the experimental
stage, including hematopoietic stem cell (HSC) transplantation,
which has gained widespread accepta
related disorders [
However, the bulk of cell-based therapies are currently in the
experimental stage. It is possible to classify cell treatments according to the particular medical disorders that they are intended to
treat, such as neurological, cardiovascular, or ophthalmological
conditions. In addition, they can be categorized according to
whether the cells that are utilized are removed from the same
individual and then returned to them (autologous) or whether
they are obtained from a donor (allogeneic). There is also the
usual practice of classifying cell therapies according to the types of
cells that are utilized. Only a small number of cell-based medications have made it to the latter stages of clinical testing and marketing authorization [
medicines are still in the early stages of research. This is still a
developing area of science proved by the experience that is now
being gained in this sector. As a result, it is of the utmost
ell therapy represents a
). C
in
the field of medicine, aligning with
nce as a treatment for blood-
1, 2].
This indicates that the majority of cell-based
3].
Cell-Based Therapies and Drug Delivery: Advancements and Challenges 475
Fig. 2 Cell therapy based on stem cells and non-stem cells
importance to have a constant process of learning and improvement, which requires close coordination between trial physicians
and laboratory researchers. The purpose of this collaboration is to
conduct an analysis of the data gathered from the preliminary
clinical trials and then make use of that information to improve
the product’s quality, which will ultimately result in the creation of
more sophisticated remedies. In the field of gene-modified T cells,
specificall
antigen receptor (CAR) T
y in the procedure of developing anti-CD19 chimeric
-cell treatments, specific examples of
this phenomenon can be observed. B-cell leukemias have been
successfully treated with these therapies, which entail the modification of T cells genetically in order to enable them to recognize the
CD19 antigen that is present on B cells. These therapies have
shown a remarkably high level of efficiency. More than 20 years of
clinical research and repeated cyc
tory have led
to the creation of these medicines [
2 Technologies Utilizing Cells in Treating Diseases
It is increasingly clear that the field of cell treatment will undergo
significant changes in the future. The remarkable effectiveness of
les of improvement in the labora-
4–6].
476 Pradeep Kumar Ram et al.
immune cell therapy has been widely observed, contributing to its
growing potential. Recent discoveries in immune cell-based treatments demonstrate the use of viral vector transduction technology
to introduce modified genes into T cells [
precise
1970s,
the
technology, which has since been refined and adapted for various
applications, including its use in the medical field. During the late
1990s and early 2000s, this technology was first used in the early
stages of in vivo gene treatments, resembling the work of a neuroscientist. Furthermore, it is currently being emplo
of cell therapy. The groundbreaking technology has undergone
significant improvements and is now being
applications. Instead of solely focusing on specific cell types, it
could be advantageous to approach the topic of cell therapy from
a technological perspective. To effectively analyze the different
technologies used in cell therapy, it is helpful to categorize each
methodology into specific technology domains.
Following is a list of classifications that are offered for technologies that utilize cells in a variety of different ways to treat diseases,
along with a brief explanation of each technological domain:
aim
of
targeting
scientists
7
his is done with the
]. T
par
ticular
made
significant advancements in viral vector
for
ms
of
blood
cancers.
yed in the realm
utilized in therapeutic
During
2.1 Somatic Cell Technologies
(a) Methods via which somatic cells are utilized
(b) The technologies that can be used to achieve cell immortality
(c) Modification of cells outside of living organisms through the
use of viral vector technology
(d) The use of methods that involve viral vector technology for
the alteration of genes in living organisms
(e) Technologies that allow for the altering of genomes
(f) Methods for the manipulation of biological materials
“Somatic cell technologies” is the phrase used to describe the use of
advanced instruments and methods to the manipulation and investigation of all bodily cells, except reproductive cells. In order to
create a specific cell product, this method uses cells that have been
isolated, multiplied, and/or differentiated from the body. After
that, a patient receives the product in order to carry out targeted
therapeutic therapy. As such, the technological difficulties involved
in translation are similar, and this is true regardless of the variety of
cell types that fall within this group of technologies. These cells
include chondrocytes, platelets, and red blood cells. Tissue stem
cells are also included in this group of cells; they include skin stem
cells, mesenchymal stem cells, and hematopoietic stem cells (HSC).
Even while the methods for differentiation, propagation, and purification may be highly sophisticated, overall technological innovation is frequently fairly low. For a considerable amount of time,
certain treatments that utilize this technology—such as blood
Cell-Based Therapies and Drug Delivery: Advancements and Challenges 477
transfusions and bone marrow transplants—have been acknowledged as the most successful options. These treatments have historically been chosen because of how simple it is to reach and use
these cells for beneficial purposes. Worldwide, a number of additional cell types, such as chondrocytes and skin stem cells, are
presently being used in therapeutic settings. Translational scientists
place a high importance on MSCs and their subpopulations, and
clinical trials
progenitor cells
are presently underway worldwide. There is hope that
or other stem cells targeted to particular tissues
would prove to be effective therapeutics. There are several applications for these cells. Every tissue has a relatively small quantity of
stem cells in it. One of the reasons it is challenging to produce a
significant amount of stem cells is that it seems that these cells’
capacity to divide is hampered when they are taken out of the body.
The resolution of
commercial feasibility
these major obstacles is required to achieve
for any treatment of this kind. Numerous
varieties of immune cells are now being produced as cell therapies.
These include macrophages, dendritic cells, gamma- delta T cells,
regulatory T cells (Treg), tumor infiltrating lymphocytes (TILs),
and viral reconstitution T cells. These cell types have experienced
several phases of development over the course of clinical trials. Even
though these immune c
technologies, there
ells fall under the category of somatic cell
may be more complicated issues involved in
implementing their utilization than are frequently seen in this
field. Conversely, T cells that have undergone genetic alteration
via the use of viral vectors are categorized as belonging to a distinct
technology category because of the specific type of modification
that was applied.
2.2 Immortalized Cell Lines
Among the many examples of this technical field, the brain stem cell
line CTX is a particularly noteworthy example. The CTX cell line is
a clonal cell line that had its origins in the cortical brain tissue of
embryonic brains. The c-mycERTAM transgene, which consisted
of a single copy, was delivered into the organism through the
process of retroviral infection. The c-mycERTAM method permits
the efficient creation of CTX cells on a large scale. This is accomplished through the implementation of conditional regulation
through the utilization of 4-hydroxytamoxifen (4-OHT). Despite
the fact that immortalization techniques have been around for a
considerable amount of time, they are not currently being utilized
in the field of cell therapy to a significant extent. In the event that
the clinical study that is now being conducted turns out to be
successful, it is extremely probable that there will be a larger
emphasis placed on this particular field of technology [
8].
478 Pradeep Kumar Ram et al.
2.3 Ex Vivo Gene
Modification of Cells
Using Viral Vector
Technologies
2.4 In Vivo Gene
Modification of Cells
Using Viral Vector
Technologies
Ex vivo gene modifications made with viral vector technology are
utilized for cell therapy applications in a variety of cell types, with T
cells, HSCs, and MSCs being the most common cell types using
this technique. The modification of genes in hematopoietic stem
cells (HSCs) has the potential to be used in the treatment of
diseases such as adenosine deaminase severe combined immunodeficiency disease (ADA SCID). In addition, gene-modified mesenchymal stem cells, also known as MSCs, are currently being
evaluated in preliminary clinical trials for the treatment of many
illnesses, including advanced cancer [
9]. With regard to T cells,
which now hold the preeminent position in this area of technology,
the technique entails genetically changing the T cells in a variety of
different ways in order to specifically target and activate them. This
ultimately results in the targeted destruction of a wide range of
various malignancies. At this time, pharmaceutical companies are
aggressively working to translate gene-modified T-cell treatments
into clinical practice. On the other hand, there is a pressing requirement to expand the capacity for the production of viral vectors as
well as transduced T cells in accordance with good manufacturing
procedures (GMP).
Introducing genetic material into the body in a direct manner is
what in vivo gene therapy is all about. Using modified viruses with
targeted viral vectors has become a widely used delivery approach
worldwide. Through the process of in vivo infection, these vectors
are introduced into cells, just as a biologist would observe and
analyze. Various types of viral vectors, such as retroviral, lentiviral,
adenoviral, and adeno-associated viral (AAV) vectors, are com-
With
monly used in advanced treatment medicinal products [
10].
its versatile capabilities, viral vector technology can be used in a
wide range of cell types to achieve specific therapeutic goals. There
are a number of possible applications for gene therapy, some of
which include the treatment of cancer, neurological illnesses,
genetic disorders, infectious diseases, and anomalies in the cardiovascular system. As the subject of technology is so vast and complex, there are a number of unique challenges that arise when
trans
lating words and phrases. It is important to note that establishing cell targeting specificity and maintaining regulated expression
are among the most significant challenges that many medicines that
are now in the process of being developed must overcome. It is a
well-established technique that holds substantial potential in the
field of cell-based therapies. Gene therapy, which is also known as
genetic treatment, is another name for this technological
advancement.